Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
Active Not Recruiting
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/11/2025
Locations: Research Site, Phoenix, Arizona +174 locations
Conditions: Non Small Cell Lung Cancer NSCLC
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Active Not Recruiting
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Gender:
ALL
Ages:
Between 18 years and 105 years
Trial Updated:
06/09/2025
Locations: Research Site, Scottsdale, Arizona +293 locations
Conditions: Advanced or Metastatic Breast Cancer
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Active Not Recruiting
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/06/2025
Locations: Research Site, Anaheim, California +210 locations
Conditions: Non Small Cell Lung Carcinoma NSCLC
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Active Not Recruiting
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, wi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Alabama - Birmingham ( Site 3061), Birmingham, Alabama +230 locations
Conditions: Endometrial Neoplasms
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
Completed
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to tr... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Arizona Oncology Associates, PC- HAL, Phoenix, Arizona +168 locations
Conditions: Endometrial Neoplasms
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Active Not Recruiting
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/15/2025
Locations: Research Site, Whittier, California +259 locations
Conditions: Triple Negative Breast Neoplasms
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska +515 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma.
Recruiting
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Siteman Cancer Center, Saint Louis, Missouri +24 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Terminated
The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated mPDAC.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/08/2025
Locations: Winship Cancer Institute, Atlanta, Georgia +30 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Atezolizumab Trial in Endometrial Cancer - AtTEnd
Completed
Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1. In May 2016 atezolizumab was approved by the FDA for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant); in October 2016 it was approve... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Royal Adelaide hospital, Adelaide, Not set +92 locations
Conditions: Endometrial Cancer
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Active Not Recruiting
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Site 318, Phoenix, Arizona +116 locations
Conditions: Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
Completed
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/10/2025
Locations: Research Site, Brussels, Not set +3 locations
Conditions: Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel